Can malignant glioma be cured if it is discovered early?

For us, having a tumor is undoubtedly a bolt from the blue, and we feel that our entire life has lost hope, especially for malignant tumors like gliomas, which require early detection and early treatment to have hope of cure. So, can malignant gliomas be cured if they are detected early?

At present, it is believed that if patients with malignant tumors can achieve the "three early" treatment, the comprehensive treatment effect is satisfactory. For example, the cure rates of stage I cervical cancer, breast cancer, gastric cancer, esophageal cancer, and nasopharyngeal cancer are all above 90%. The cure rates of early choriocarcinoma and early seminoma tumor cell tumors have reached or are close to 100%. Liver cancer, known as the "king of cancer", is now also possible to be cured. The five-year cure rate of early micro-liver cancer has reached more than 70%. Some tumors have a chance of being cured even in the late stage. For example, the five-year cure rate of advanced choriocarcinoma is 83% for stage III patients and 53% for stage IV patients.

With the strengthening of people's awareness of cancer prevention and treatment, the continuous control of knowledge on brain tumor prevention, coupled with the continuous improvement of clinical diagnosis and treatment techniques, and the application of combined Chinese and Western medicine treatment, many patients with malignant tumors have been cured, and countless cancer patients are in the recovery period. Ginsenoside Rh2 is the most commonly used Chinese medicine in combined Chinese and Western medicine treatment. It has immunomodulatory effects, inhibits the growth and spread of cancer cells, induces cancer cell apoptosis, and reverses the abnormal differentiation of cancer cells. In combination with Western medicine treatment, it can play a good role in enhancing efficacy and reducing toxicity, thereby alleviating the pain of patients, prolonging their lives, and increasing the cure rate of patients with brain gliomas.

The effect of drugs for treating glioma is not satisfactory. One of the main reasons is that it is not easy to penetrate the blood-brain barrier and it is difficult to reach the lesion site. Solutes in the blood must pass through the endothelial cells of the brain capillaries to reach the brain tissue. The endothelial cell membrane is a bilayer membrane structure based on lipids, which is lipophilic and easy for fat-soluble substances to pass through. Therefore, the fat solubility of solutes in the blood determines the difficulty and speed of passing through the barrier. The higher the fat solubility, the faster the solute passes through the barrier and enters the brain tissue. Ginsenoside Rh2 is a small molecule substance because it is highly fat-soluble and has few hydroxyl groups. It is easier to pass through the lipophilic endothelial cell membrane to reach the brain tissue and exert its tumor-inhibiting effect more quickly. Therefore, compared with many drugs for treating glioma, ginsenoside Rh2 has the huge advantage of being able to penetrate the blood-brain barrier, with high bioavailability and good absorption. In addition, ginsenoside Rh2 is naturally non-toxic, which can reduce the toxic and side effects of chemotherapy drugs and help patients improve their own immunity.

Literature has reported that the invasive growth of glioma is a complex process involving multi-step and multi-stage interactions between tumor cells and their extracellular matrix components. Ginsenoside Rh2 is a natural ingredient extracted from ginseng. It is a small molecule and fat-soluble substance that can easily pass through the blood-brain barrier. Experiments have also confirmed that ginsenoside Rh2 can inhibit the growth of gliomas in vivo and prolong the survival time of tumor-bearing mice.

Professors from the Medical University conducted experiments to observe the effect of ginsenoside Rh2 on the proliferation of C6 glioma cells. The results showed that ginsenoside Rh2 had an inhibitory effect on the proliferation of C6 glioma cells, and it showed a significant dose-effect relationship; after the action of ginsenoside Rh2, the percentage of cells in the G0/G1 phase decreased significantly, while the percentage of cells in the S phase increased significantly. This shows that ginsenoside Rh2 has a significant inhibitory effect on the proliferation and induction of apoptosis of C6 glioma cells, and this effect is cycle-specific. Ginsenoside Rh2 can easily pass through the blood-brain barrier, so it can also be used in combination with other cell cycle-specific drugs to improve the chemotherapy effect of gliomas.

Cell apoptosis is an active physiological process, just like the blooming and falling of flowers, which ultimately achieves a healthy balance in the human body. Although the causes of glioma are complex, the root cause is the disruption of the balance of cell apoptosis, which leads to abnormal cell proliferation. Experiments have confirmed that the balance messenger ginsenoside Rh2 can penetrate the blood-brain barrier, induce apoptosis of glioma cells, and restore normal cell proliferation, thereby effectively treating glioma.